ALAN H. HALL, M.D.; SUSAN C. SMOLINSKE, B.S., R.Ph.; KENNETH W. KULIG, M.D.; BARRY H. RUMACK, M.D.
Guanabenz (2,6-dichlorobenzylidene aminoguanidine acetate; Wytensin; Wyeth Laboratories, Philadelphia, Pennsylvania) is a centrally acting, selective, alpha2-adrenergic agonist combining the substituted benzene ring of clonidine with the aminoguanidine sidechain of guanethidine (1). The hypotensive and bradycardic effects of this new antihypertensive agent are mediated by stimulation of postsynaptic inhibitory receptors in the central nervous system, which results in decreased peripheral sympathetic tone (1). Therapeutic doses range from 8 to 96 mg/d for adults and 3 to 13 mg/d for children (2, 3). Experience with guanabenz overdose is limited. Animal studies of overdose have shown sedation, cardiac depression, ataxia, hyperglycemia, and hypothermia (1).
HALL AH, SMOLINSKE SC, KULIG KW, RUMACK BH. Guanabenz Overdose. Ann Intern Med. ;102:787–788. doi: 10.7326/0003-4819-102-6-787
Download citation file:
Published: Ann Intern Med. 1985;102(6):787-788.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use